Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
The GeneSearch Breast Lymph Node assay has been shown to have higher sensitivity and specificity in detecting breast cancer metastases compared to traditional intra-operative tests. The test's accuracy enables surgeons to make more informed treatment decisions and potentially reduce the need for second surgeries.
A monoclonal antibody JAA-F11 has been shown to extend the survival of mice with human breast-cancer tumors and inhibit their spread to the lungs, a result attributed to its ability to block adhesion and growth stages of cancer cells.
A team of researchers from CNSE and Einstein College of Medicine are developing a next-generation microchip to detect metastatic cells in tumors, enabling more aggressive cancer therapy. The device will be assembled from nanoscale components and implanted in human tumors to gather information on cancer cell behavior.
Researchers at Einstein and U. Albany will create a microchip to detect metastatic cells in human tumors, enabling more aggressive cancer therapy. The project aims to improve understanding of tumor microenvironments and cancer spread.
A new procedure at UCLA's Jules Stein Eye Institute uses fine-needle aspiration to collect cancer cells from the living eye and predict high-risk tumors. The test has shown promise in reducing mortality rates among ocular melanoma patients.
The University of Chicago Medical Center will focus on metastasis with a $20 million donation from the Virginia & D.K. Ludwig Fund for Cancer Research. Researchers aim to unravel what makes cancer susceptible to metastasis and develop new treatments.
A study found that adding radiation therapy after prostate gland removal reduced PSA relapse and disease recurrence risk by 50% and 38%, respectively. However, it did not improve overall survival or metastasis-free survival.
Researchers found that pre-surgical treatment with bevacizumab and erlotinib is safe and effective in prolonging patients' survival. The study suggests this approach might be applicable to a wide range of patients with renal cell carcinoma.
Researchers found that higher doses of 74-82 Gray radiation significantly reduce the risk of prostate cancer spreading to other parts of the body, even 8-10 years after treatment. Treatment centers using IMRT or 3D conformal radiation therapy with high doses can prevent cancer spread.
Researchers have developed a new method to detect metastasizing melanoma cells in the blood using photoacoustic detection, which can identify as few as 10 cancer cells. The technique uses laser techniques and ultrasound methods to emit noise from cancer cells, allowing for early diagnosis and treatment.
The study reveals that tissue geometry controls the morphogenesis of breasts and other organs by defining local cellular branching microenvironments. This finding may reveal mechanisms to control cancer invasion and metastasis.
Researchers have identified a new marker, AZGP1, that can predict which men with prostate cancer are likely to develop aggressive metastatic disease. This marker can help tailor treatment for individual patients and improve outcomes.
Researchers found radiofrequency ablation effective in achieving local control in selected patients with advanced ovarian cancer. The procedure resulted in complete necrosis in five of six patients, with no evidence of recurrence after treatment.
Newly discovered behavior in cancer cells reveals a toggle switch that enables them to morph into highly mobile cells, invade other tissues, and adapt comfortably. This understanding could lead to finding ways to stop metastasis, the most deadly trait of cancer.
A new technology can detect one malignant cell in a typical blood sample, enabling early adjustment of treatment to target spreading cancer. This diagnostic tool has a 97% specificity and may revolutionize the prevention of cancer death.
A study has identified molecular markers in RNA and DNA that can detect small metastases from ocular melanoma, allowing for early intervention. Fine needle biopsy is a feasible method to accurately detect these markers, enabling clinicians to identify high-risk patients who may benefit from targeted treatments.
A new study found that liver cancer metastasis is influenced by the local tissue's microenvironment, with a unique gene expression signature predicting metastatic potential. The researchers identified a key role for colony-stimulating factor 1 in promoting anti-inflammatory conditions supporting tumor growth and metastasis.
Researchers at Thomas Jefferson University have identified proepithelin as a crucial protein in the spread of bladder cancer. The study found that proepithelin promotes migration and invasion of bladder cancer cells, suggesting it could be a potential target for new drugs.
A new study uses a 3D model to reveal the secrets of metastasis in human prostate tumor cells. Cells move slower and need to chop or squeeze through fibers to progress. The research provides insights into why two-dimensional assays for metastasis-inhibiting drugs are not effective.
Eleven researchers received grants to accelerate the discovery and development of new agents for treating metastatic colon cancer. The study aims to identify mechanisms in colon cancer that make tumor cells resistant to apoptosis, as well as develop combination drug therapies to reverse the apoptotic defect.
Scientists have identified a novel gene NEDD9 that facilitates the spread of malignant melanoma. This gene is abnormally abundant in more than a third of melanomas that have metastasized, but not in primary melanomas.
Researchers identified two genes that can produce liver cancer and a gene important to melanoma spread. Genes in these pathways are promising targets for cancer drugs, according to the study. Improvements in genome technology have enabled researchers to filter out non-causal genetic changes and focus on functionally relevant ones.
A simple and inexpensive test identifies tumours with protein IMP3, predicting cancer spread, allowing for targeted treatment. Patients with these tumours are six times more likely to develop metastasis and four times more likely to die after surgery.
Researchers found a novel tumor suppressor, HLJ1, that slows down lung cancer cell proliferation and reduces cancer recurrence. Patients with high HLJ1 expression lived longer than those with low expression.
A new test has been developed to detect prostate cancer spread in lymph nodes at an earlier stage, which may lead to better treatments and improved patient outcomes. The test was found to be more sensitive than existing methods and associated with increased recurrence and decreased survival rates.
Researchers reviewed data from 156 patients with inflammatory breast cancer and found that a standard combination of therapies did not significantly increase survival rates. The study highlights the need for further research to identify subsets of patients who may benefit from alternative treatment approaches.
Researchers compared WBRT plus SRS to SRS alone in patients with limited brain metastases. The study found that SRS alone was associated with increased brain tumor recurrence but not worsened neurologic function or increased risk of death. Frequent monitoring of brain tumor status is recommended for this treatment option.
Researchers found that a new drug, imatinib, destroys the blood vessels that feed prostate cancer cells, preventing tumor growth and metastasis. In a mouse model, tumors were significantly reduced when treated with a combination of imatinib and chemotherapy.
A phase 2 trial confirms the antitumor efficacy of sunitinib in patients with metastatic clear-cell RCC refractory to cytokine therapy. Sunitinib achieved a 34% partial response rate and median progression-free survival of 8.3 months.
The study demonstrated a statistically significant benefit of FOLFIRI in patients with metastatic colorectal cancer, improving progression-free survival and overall survival. Adding bevacizumab to FOLFIRI also showed improved outcomes, with a higher percentage of patients alive after one year.
Researchers identified 254 gene sequences in melanomas that may inhibit metastasis and found high retinol levels reduce risk of hepatocellular carcinoma. Grb7 peptide inhibitor targets pancreatic cancer cells, showing promise as a new therapy.
Researchers found that waves in cancer cells selectively round up activated growth-promoting proteins, which can help terminate signals and prevent cancerous traits. This discovery provides new insights into the role of waves in cancer cell metastasis.
Researchers found that MMP-9 is highly expressed by colon cancer cells and is key to initiating metastasis. By blocking the enzyme, colorectal cancer cells cannot metastasize to other tissue, suggesting a new target for preventing metastasis in colon cancer.
Researchers have discovered a potential new treatment for breast cancer metastasis to bone, where 70% of patients develop bone metastases. The study found that osteoprotegerin inhibits RANKL, a protein promoting bone breakdown and cancer cell growth.
The study found that patients receiving the combination of paclitaxel and bevacizumab had a significantly improved progression-free survival of 11.4 months, compared to 6.11 months with paclitaxel alone. This trend also suggested improved overall survival in patients treated with the new drug combination.
Researchers at Karolinska Institutet have identified a short peptide molecule that can vaccinate and protect against the spread of tumours from different tissues, including melanoma, colon cancer, lymphoma, and fibrosarcoma. The study points towards new possible ways of developing a treatment for advanced tumour diseases.
Using a chick model, researchers demonstrated that malignant melanoma cells can respond to and be influenced by the embryonic neural-crest-rich microenvironment. This discovery may hold promise for developing new treatments for metastatic melanoma.
A new clinical trial at Northwestern Memorial Hospital aims to evaluate the effectiveness of combining chemotherapy and radiation therapy with Avastin in reducing tumor size and increasing survival rates. The two-year study will enroll 40 participants with localized pancreatic cancer.
Researchers analyzed 28,689 cases of non-small cell lung cancer, finding a stronger association between tumor size and metastasis for solid tumors. The study suggests that smaller tumor sizes are associated with higher curability rates, even for micrometastases undetectable by current techniques.
Researchers found that post-lactation involution matrix promotes breast tumor cell migration and metastasis, even when compared to virgin matrix. The study suggests changes in the breast environment during pregnancy may contribute to poor breast cancer outcomes.
Researchers at OHSU have discovered a protein fragment, p95HER-2, which closely correlates with lymph node metastasis and earlier recurrence of breast cancer. The study suggests that p95HER-2 is a marker for metastasis and may help identify patients with longer disease-free survival.
Tumor cells that border normal tissue exhibit distinct behavior, losing surface proteins and gaining the ability to dissolve matrix surrounding cells. This change signals activation of proteins allowing tumor cells to migrate, posing a risk for metastasis. The discovery highlights the importance of tumor environment in cancer progression.
Researchers found that the loss of caspase-8 protein promotes neuroblastoma metastasis by allowing cancer cells to break away from the primary tumor and spread to other sites in the body. Novel treatments that restore the tumor-suppression role of caspase-8 may prevent metastases and improve patient outcomes.
Researchers have identified a gene called caspase 8 that plays a crucial role in preventing tumor cells from metastasizing, or spreading to distant sites. By activating this mechanism, the researchers aim to develop targeted therapies to halt the spread of neuroblastoma and possibly other cancers.
A study found that nearly half of patients treated with the PC combination experienced a clinical benefit, including stable disease and tumor size reduction. Researchers believe this combination has a beneficial role, especially for patients with poor treatment outcomes.
Researchers have discovered that transforming growth factor beta (TGF-ß) regulates bone matrix properties, which affect bone elasticity, toughness, and resistance to fracture. The study suggests that targeting TGF-ß signaling could improve bone quality, potentially preventing osteoporosis and improving bone repair.
Cancer cells hybridize with macrophages to exhibit traits such as migration and blood supply formation. The study provides new insights into metastasis, a process previously attributed to tumor cell fusion.
A new study in mice found that chronic stress and UV radiation suppress the immune system, leading to increased tumor formation and quicker disease progression. Researchers observed suppression of T-cell function and type 1 cytokines, highlighting the potential for chronic stress to increase cancer risk.
ZBP1 guides actin messenger RNA to cell periphery and regulates translation into protein. The enzyme Src adds a phosphate group to ZBP1, unlocking the mRNA for translation into actin protein. This discovery could lead to new cancer therapies by targeting ZBP1 expression.
Researchers discovered AKT paradoxically blocks cancer cell motility and invasion abilities, preventing cancer spread. The study's findings suggest targeting AKT may increase cells' properties of motility and invasiveness.
Researchers developed a model that reprograms benign skin cells to express genes associated with aggressive melanoma cells, highlighting the role of tumor cell microenvironment in transformation. The study provides potential therapeutic strategies to inhibit melanoma spread.
Researchers at Northwestern University have discovered a potential target for preventing metastatic melanoma, the cancer's ability to spread and be fatal. The study identified focal adhesion kinase (FAK) as a key player in promoting aggressive melanoma behavior.
Treating four or more brain tumors with radiosurgery is safe and effective, translating to a survival benefit of up to 18 months for some patients. The study's findings suggest that tumor volume rather than the number of brain metastases should be used as a criterion for radiosurgery.
A recent study examined mortality and complications within 30 days following radical prostatectomy in 11,010 men who underwent the surgery between 1990 and 1999. The study found that age was associated with an increased risk of 30-day mortality, but the absolute risk of death was low even among men ages 70 to 79.
Scientists have identified a new compound in cranberries that prevents cancer cells from breaking away and spreading to other parts of the body. The compound inhibits the growth of human lung, colon, and leukemia cells in culture without affecting healthy cells.
Researchers discovered that a specific gene variant can arise as a mutation during cancer development, contributing to tumor growth and spread. The study found the variant in nearly half of liver metastatic tumors, suggesting it may be an important target for new therapies.
Scientists at The Wistar Institute have identified the cancer gene MYC as activating the metastasis gene MTA1, a key regulator of tumor spread. Blocking this pathway may prevent metastasis and inform the development of new therapies.
The study found two relapse peaks after surgery for breast cancer, with 20% of premenopausal patients relapsing within 10 months. Calculations predict that surgery-induced angiogenesis accelerates disease by two years and produces early deaths among screened young women.
Researchers at Sunnybrook Hospital have developed a unique mouse model that enables scientists to study how breast cancer spreads. By analyzing the genetic makeup of tumour cells, they hope to predict which tumours will metastasize and develop new treatments.
Researchers found RhoC essential for tumor metastasis, but dispensable for embryonic development and tumor initiation. RhoC-deficient mice display reduced tumor metastasis, lower cell motility, and survival properties in secondary sites.